PEMGARDA Net Product Revenue (Q3 2024)

Not applicable (sequential change from Q2 2024)

The increase from $2.3 million in Q2 2024 to $9.3 million in Q3 2024 reflects Invivyd’s transition from a clinical-stage company (with no significant revenue previously " ) to a product commercialization phase. The growth is attributed to ongoing commercial optimization, including expanded healthcare outreach, increased points of care, and new support programs for patients. " "

Total Revenue (Q4 2024)

Not applicable (sequential increase ~48% from Q3 2024)

The sequential momentum is demonstrated by a ~48% rise from Q3 2024’s $9.3 million to $13.8 million in Q4 2024, driven entirely by the PEMGARDA product segment. This further improvement builds on the Q3 performance and reflects effective commercialization initiatives and continued market penetration. "